-
公开(公告)号：US5773253A
公开(公告)日：1998-06-30
申请号：US505058
申请日：1995-07-21
IPC分类号： C12N15/09 , A61K38/00 , C07H21/04 , C07K1/22 , C07K14/495 , C07K14/52 , C07K14/525 , C07K14/53 , C07K14/54 , C07K14/55 , C07K14/555 , C07K14/705 , C07K14/715 , C07K14/725 , C07K16/00 , C07K16/18 , C07K19/00 , C12N5/06 , C12N5/10 , C12N15/12 , C12P21/02 , C12R1/91
CPC分类号： C07K14/7155 , C07K14/70521 , A61K38/00 , C07K2319/00 , C07K2319/30
摘要： The invention provides CTLA4 mutant molecules as ligands for the B7 antigen. Methods are provided for expressing CTLA4 mutant molecules as soluble, functional molecules, for preparing CTLA4 mutant fusion proteins, and for using these soluble molecules to regulate T cell interactions and immune responses mediated by such interactions.
摘要翻译： 本发明提供CTLA4突变体分子作为B7抗原的配体。 提供了用于表达CTLA4突变体分子作为可溶性功能分子的方法，用于制备CTLA4突变融合蛋白，以及使用这些可溶性分子调节由这种相互作用介导的T细胞相互作用和免疫应答。
-
52.发明授权Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell 失效编码双特异性融合蛋白的表达载体和在哺乳动物细胞中产生生物活性双特异性融合蛋白的方法
公开(公告)号：US5637481A
公开(公告)日：1997-06-10
申请号：US121054
申请日：1993-09-13
申请人： Jeffrey A. Ledbetter , Lisa K. Gilliland , Martha S. Hayden , Peter S. Linsley , Jurgen Bajorath , H. Perry Fell
发明人： Jeffrey A. Ledbetter , Lisa K. Gilliland , Martha S. Hayden , Peter S. Linsley , Jurgen Bajorath , H. Perry Fell
IPC分类号： C07K14/705 , A61K38/00 , C07K14/00 , C07K14/16 , C07K14/715 , C07K16/00 , C07K16/28 , C07K16/30 , C07K16/46 , C07K19/00 , C12N5/10 , C12N15/09 , C12N15/13 , C12N15/62 , C12P21/02 , C12P21/08 , C12R1/91 , G01N33/563 , G01N33/569 , G01N33/574 , C12N15/79 , C12P21/00
CPC分类号： C07K14/005 , C07K14/70521 , C07K14/7155 , C07K16/00 , C07K16/2809 , C07K16/2818 , C07K16/2827 , C07K16/30 , C07K16/468 , C12N15/62 , G01N33/563 , G01N33/56972 , G01N33/57492 , A61K2039/505 , A61K38/00 , C07K2317/31 , C07K2317/34 , C07K2317/622 , C07K2317/732 , C07K2317/734 , C07K2317/74 , C07K2319/00 , C07K2319/02 , C07K2319/30 , C07K2319/43 , C12N2740/16122 , G01N2333/705
摘要： The present invention provides an expression vector encoding monospecific or bispecific fusion protein. In one embodiment the expression vector encodes a monospecific fusion protein, which vector comprises a recombinant monospecific single chain cassette comprising a DNA sequence encoding a first binding domain capable of binding a cell surface antigen.
摘要翻译： 本发明提供编码单特异性或双特异性融合蛋白的表达载体。 在一个实施方案中，表达载体编码单特异性融合蛋白，该载体包含重组单特异性单链盒，其包含编码能够结合细胞表面抗原的第一结合结构域的DNA序列。
-
公开(公告)号：US5540926A
公开(公告)日：1996-07-30
申请号：US940605
申请日：1992-09-04
IPC分类号： A61K38/00 , A61K39/395 , A61P37/04 , A61P43/00 , C07K14/00 , C07K14/47 , C07K14/52 , C07K14/705 , C07K14/725 , C07K16/28 , C07K19/00 , C12N5/06 , C12N15/09 , C12N15/12 , C12P21/02 , C12P21/08 , A61K38/17
CPC分类号： C07K14/70575 , C07K14/70517 , C07K14/7056 , C07K16/2878 , A61K38/00 , C07K2317/73
摘要： The present invention relates to soluble ligands for the B-cell antigen, CD40, and, in particular, to human gp39 protein and soluble ligands derived therefrom which may be used in methods of promoting B-cell proliferation.
摘要翻译： 本发明涉及可用于促进B细胞增殖的方法中的B细胞抗原的可溶性配体，CD40，特别是涉及人gp39蛋白和由其衍生的可溶性配体。
-
公开(公告)号：US4677061A
公开(公告)日：1987-06-30
申请号：US662878
申请日：1984-10-19
IPC分类号： G01N33/569 , C12Q1/06 , G01N33/566
CPC分类号： G01N33/56972 , Y10S435/968
摘要： Methods and compositions are provided for determining a change in status of a multiple sclerosis victim. Particularly, the ratio of helper or suppressor T cell subsets having specific surface markers associated with proliferation is determined, where a particular ratio value is associated with a change in status.
摘要翻译： 提供了用于确定多发性硬化症患者状态变化的方法和组合物。 特别地，确定具有与增殖相关的特异性表面标志物的辅助或抑制T细胞亚群的比例，其中特定比值与状态变化相关联。
-
公开(公告)号：US10202588B2
公开(公告)日：2019-02-12
申请号：US13822215
申请日：2012-04-27
摘要： Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
-
公开(公告)号：US08853366B2
公开(公告)日：2014-10-07
申请号：US13396147
申请日：2012-02-14
IPC分类号： A61K39/00
CPC分类号： C07K16/3061 , A61K38/00 , A61K39/0011 , A61K2039/505 , A61K2039/5152 , A61K2039/5156 , A61K2039/5158 , C07K16/2809 , C07K16/2818 , C07K16/2878 , C07K16/2896 , C07K16/462 , C07K2317/22 , C07K2317/24 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/30 , C12N5/0636 , C12N2501/23 , C12N2501/51 , C12N2501/515 , C12N2501/52 , C12N2502/11 , C12N2510/00
摘要： The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high express levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.
摘要翻译： 本发明涉及新颖的结合域 - 免疫球蛋白融合蛋白，其特征在于用于诸如抗原，反向受体等的同源结构的结合结构域，野生型IgG1，IGA或IgE铰链区多肽或突变型IgG1铰链区多肽 具有零个，一个或两个半胱氨酸残基，以及免疫球蛋白CH2和CH3结构域，并且它们能够以ADCC和/或CDC的形式发生，同时主要作为其形成二硫键连接的多聚体的能力被损害的多肽。 融合蛋白可以以高表达水平重组生产。 还提供了相关的组合物和方法，包括融合蛋白的细胞表面形式和融合蛋白的免疫治疗应用以及编码这种融合蛋白的多核苷酸。
-
公开(公告)号：US08409577B2
公开(公告)日：2013-04-02
申请号：US12304562
申请日：2007-06-12
申请人： Peter Armstrong Thompson , Jeffrey A. Ledbetter , Martha Susan Hayden-Ledbetter , Laura Sue Grosmaire , Robert Bader , William Brady
发明人： Peter Armstrong Thompson , Jeffrey A. Ledbetter , Martha Susan Hayden-Ledbetter , Laura Sue Grosmaire , Robert Bader , William Brady
CPC分类号： C07K16/28 , A61K2039/505 , A61K2039/507 , C07K16/18 , C07K16/2803 , C07K16/2809 , C07K16/2818 , C07K16/2827 , C07K16/2833 , C07K16/2851 , C07K16/2875 , C07K16/2878 , C07K16/2887 , C07K16/2896 , C07K16/30 , C07K16/46 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2317/732 , C07K2317/734 , C07K2319/30
摘要： Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.
摘要翻译： 提供具有免疫球蛋白效应子功能的多价结合肽，包括双特异性结合肽，以及编码核酸，载体和宿主细胞以及制备这些肽的方法和使用这些肽治疗或预防各种疾病的方法 ，疾病或病症，以及改善与这种疾病，病症或病症相关的至少一种症状。
-
公开(公告)号：US20110223164A1
公开(公告)日：2011-09-15
申请号：US13039097
申请日：2011-03-02
CPC分类号： C07K16/3061 , A61K38/00 , A61K39/0011 , A61K2039/505 , A61K2039/5152 , A61K2039/5156 , A61K2039/5158 , C07K16/2809 , C07K16/2818 , C07K16/2878 , C07K16/2896 , C07K16/462 , C07K2317/22 , C07K2317/24 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/30 , C12N5/0636 , C12N2501/23 , C12N2501/51 , C12N2501/515 , C12N2501/52 , C12N2502/11 , C12N2510/00
摘要： The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type lgG1, IGA or IgE hinge region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high express levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.
摘要翻译： 本发明涉及新颖的结合域 - 免疫球蛋白融合蛋白，其特征在于同源结构的结合域如抗原，反向受体等，野生型IgG1，IGA或IgE铰链区多肽或突变型IgG1铰链区多肽 具有零个，一个或两个半胱氨酸残基，以及免疫球蛋白CH2和CH3结构域，并且它们能够以ADCC和/或CDC的形式发生，同时主要作为其形成二硫键连接的多聚体的能力被损害的多肽。 融合蛋白可以以高表达水平重组产生。 还提供了相关的组合物和方法，包括融合蛋白的细胞表面形式和融合蛋白的免疫治疗应用以及编码这种融合蛋白的多核苷酸。
-
59.发明申请CD37 IMMUNOTHERAPEUTIC AND COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC THEREOF 有权CD37免疫组织化学与双功能化学疗法公开(公告)号：US20110171208A1
公开(公告)日：2011-07-14
申请号：US12678857
申请日：2009-04-11
申请人： Philip Tan , Sandy Alexander Simon , Charles G. Cerveny , Christy Anne Nilsson , William Brady , Jeffrey A. Ledbetter , Martha Susan Hayden-Ledbetter , Peter Armstrong Thompson , Cecile Morales
发明人： Philip Tan , Sandy Alexander Simon , Charles G. Cerveny , Christy Anne Nilsson , William Brady , Jeffrey A. Ledbetter , Martha Susan Hayden-Ledbetter , Peter Armstrong Thompson , Cecile Morales
IPC分类号： A61K39/395 , C07K16/00 , A61P35/00
CPC分类号： A61K39/39541 , A61K31/4184 , A61K38/16 , A61K39/39558 , A61K2039/505 , C07K16/2896 , C07K16/3061 , C07K16/461 , C07K2317/24 , C07K2317/50
摘要： The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B cell related autoimmune, inflammatory, or hyperproliferative diseases.
摘要翻译： 本公开内容提供人源化抗CD37小模块化免疫药物（SMIP）分子，以及CD37-特异性结合分子（例如抗CD37SMIP蛋白或抗体）与双功能化学治疗剂（例如苯达莫司汀）的协同组合疗法，其可以 同时或顺序施用，用于治疗或预防B细胞相关的自身免疫性，炎症性或过度增殖性疾病。
-
公开(公告)号：US20110105729A1
公开(公告)日：2011-05-05
申请号：US12901295
申请日：2010-10-08
CPC分类号： C07K16/46 , A61K2039/505 , C07K16/2809 , C07K16/2818 , C07K16/2878 , C07K16/2896 , C07K16/462 , C07K2317/22 , C07K2317/24 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/30
摘要： The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.
摘要翻译： 本发明涉及新颖的结合域 - 免疫球蛋白融合蛋白，其特征在于同源结构如结合抗原，反式受体等的结合结构域，具有零个或一个半胱氨酸残基的铰链区多肽和免疫球蛋白CH2和CH3结构域， 并且其能够主要以单体多肽的形式存在于ADCC和/或CDC。 可以以高表达水平重组产生融合蛋白。 还提供了相关的组合物和方法，包括免疫治疗应用。
-
-
-
-
-
-
-
-
-
搜索结果
85 条记录 (耗时 0.062 秒)
